June 2, 2021 07:42 AM EDTUpdated 10:59 AM

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Germany’s MorphoSys has swooped in to buy cancer drug developer Constellation $CNST in a deal that values the company at $1.7 billion. And they’re funding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Mor­phoSys swoops in with a $1.7B deal to buy Con­stel­la­tion, adds $2B-plus in Roy­al­ty pact

Editor & Founder

Editor

Sign up to read this article for free.

more like this

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact